High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities

被引：0
|
作者：
Ioannis A. Voutsadakis
机构：
[1] Algoma District Cancer Program,Section of Internal Medicine, Division of Clinical Sciences
[2] Sault Area Hospital,undefined
[3] Northern Ontario School of Medicine,undefined
来源：
Targeted Oncology | 2020年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：127 / 138
页数：11
相关论文
共 50 条
  • [31] High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers
    Riviere, Paul
    Goodman, Aaron M.
    Okamura, Ryosuke
    Barkauskas, Donald A.
    Whitchurch, Theresa J.
    Lee, Suzanna
    Khalid, Noor
    Collier, Rachel
    Mareboina, Manvita
    Frampton, Garrett M.
    Fabrizio, David
    Sharabi, Andrew B.
    Kato, Shumei
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) : 2139 - 2145
  • [32] Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden
    Cao, Yanshuo
    Ma, Yutong
    Yu, Jiangyuan
    Sun, Yu
    Sun, Tingting
    Shao, Yang
    Li, Jie
    Shen, Lin
    Lu, Ming
    CANCER COMMUNICATIONS, 2020, 40 (12) : 746 - 751
  • [33] Anticancer Properties of Baicalin against Breast Cancer and other Gynecological Cancers: Therapeutic Opportunities based on Underlying Mechanisms
    Pourhanifeh, Mohammad Hossein
    Farrokhi-Kebria, Hossein
    Mostanadi, Parsa
    Farkhondeh, Tahereh
    Samarghandian, Saeed
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17
  • [34] DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
    Hsiehchen, David
    Hsieh, Antony
    Samstein, Robert M.
    Lu, Tianshi
    Beg, Muhammad S.
    Gerber, David E.
    Wang, Tao
    Morris, Luc G. T.
    Zhu, Hao
    CELL REPORTS MEDICINE, 2020, 1 (03)
  • [35] Tissue- specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers
    Muquith, Maishara
    Espinoza, Magdalena
    Elliott, Andrew
    Xiu, Joanne
    Seeber, Andreas
    El-Deiry, Wafik
    Antonarakis, Emmanuel S.
    Graff, Stephanie
    Hall, Michael J.
    Borghaei, Hossein
    Hoon, Dave S.
    Liu, Stephen V.
    Ma, Patrick C.
    McKay, Rana R.
    Wise-Draper, Trisha
    Marshall, John
    Sledge, George W.
    Spetzler, David
    Zhu, Hao
    Hsieh, David
    CANCER RESEARCH, 2024, 84 (06)
  • [36] Rapid acquired resistance to alectinib in ALK-positive lung cancers with high tumor mutation burden
    Ohashi, Kadoaki
    Makimoto, Go
    Tomida, Shuta
    Nishii, Kazuya
    Toyooka, Shinichi
    Kiura, Katsuyuki
    CANCER RESEARCH, 2019, 79 (13)
  • [37] High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients
    Cao, Dedong
    Xu, Huilin
    Xu, Ximing
    Guo, Tao
    Ge, Wei
    ONCOIMMUNOLOGY, 2019, 8 (09):
  • [38] High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
    Voutsadakis, Ioannis A.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [39] Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
    Sammons, Sarah
    Elliott, Andrew
    Barroso-Sousa, Romualdo
    Chumsri, Saranya
    Tan, Antoinette R.
    Sledge, George W.
    Tolaney, Sara M.
    Torres, Evanthia T. Roussos
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
    Sammons, Sarah
    Elliott, Andrew
    Force, Jeremy
    Chumsri, Saranya
    Anders, Carey
    Tan, Antoinette R.
    Magee, Daniel
    Zeng, Jia
    Korn, W. Michael
    Kahsraw, Mustafa
    Torres, Evanthia T. Roussos
    CANCER RESEARCH, 2022, 82 (04)
12345